Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested Capital

Denali Therapeutics (DNLI) Assets Average (2018 - 2026)

Denali Therapeutics has reported Assets Average over the past 8 years, most recently at $1.1 billion for Q4 2025.

  • Quarterly Assets Average fell 22.2% to $1.1 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.1 billion through Dec 2025, down 22.2% year-over-year, with the annual reading at $1.3 billion for FY2025, 0.36% changed from the prior year.
  • Assets Average was $1.1 billion for Q4 2025 at Denali Therapeutics, down from $1.1 billion in the prior quarter.
  • Over five years, Assets Average peaked at $1.6 billion in Q1 2021 and troughed at $1.1 billion in Q4 2025.
  • The 5-year median for Assets Average is $1.4 billion (2022), against an average of $1.4 billion.
  • Year-over-year, Assets Average skyrocketed 152.35% in 2021 and then fell 24.85% in 2025.
  • A 5-year view of Assets Average shows it stood at $1.4 billion in 2021, then fell by 5.83% to $1.3 billion in 2022, then dropped by 11.06% to $1.2 billion in 2023, then increased by 18.3% to $1.4 billion in 2024, then dropped by 22.2% to $1.1 billion in 2025.
  • Per Business Quant, the three most recent readings for DNLI's Assets Average are $1.1 billion (Q4 2025), $1.1 billion (Q3 2025), and $1.2 billion (Q2 2025).